{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:15:50Z","timestamp":1788491750908,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13760-024-02709-4","type":"journal-article","created":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T23:30:25Z","timestamp":1735515025000},"page":"915-922","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Statins as potential disease-modifying therapy of Parkinson's disease: a systematic review and meta-analysis with trial sequential analysis"],"prefix":"10.1007","volume":"125","author":[{"given":"Oc\u00edlio Ribeiro","family":"Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arquimedes Barros","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Gon\u00e7alves","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"de Almeida Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Lu\u00eds Reis","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonatas Paulino","family":"da Cunha Monteiro Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Leal","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Victor Ara\u00fajo","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Antonnio Rocha","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo Mota","family":"Telles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1vio","family":"Sekeff-Sallem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelson James","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"5","key":"2709_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2.PMID:33894193;PMCID:PMC8185633","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W (2021) Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol 20(5):385\u2013397. https:\/\/doi.org\/10.1016\/S1474-4422(21)00030-2.PMID:33894193;PMCID:PMC8185633","journal-title":"Lancet Neurol"},{"key":"2709_CR2","doi-asserted-by":"publisher","unstructured":"Saba RA, Maia DP, Cardoso FEC, Borges V, F Andrade LA, Ferraz HB, Barbosa ER, Rieder CRM, da Silva DJ, Chien HF, Capato T, Rosso AL, Souza Lima CF, Bezerra JMF, Nicaretta D, Povoas Barsottini OG, Godeiro-J\u00fanior C, Broseghini Barcelos L, Cury RG, Spitz M, Azevedo Silva SMC, Della Colletta MV. Guidelines for Parkinson's disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms. Arq Neuropsiquiatr. 2022 Mar;80(3):316\u2013329. https:\/\/doi.org\/10.1590\/0004-282X-ANP-2021-0219. PMID: 35319667; PMCID: PMC9648930.","DOI":"10.1590\/0004-282X-ANP-2021-0219"},{"key":"2709_CR3","doi-asserted-by":"publisher","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Oct 7;390(10103):1664\u20131675. https:\/\/doi.org\/10.1016\/S0140-6736(17)31585-4. Epub 2017 Aug 3. PMID: 28781108; PMCID: PMC5831666.","DOI":"10.1016\/S0140-6736(17)31585-4"},{"issue":"1","key":"2709_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Klos K, Bordelon Y, St Hiliare MH, Shprecher D, Lee S, Dawson TM, Roschke V, Kieburtz K (2024) Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 23(1):37\u201345. https:\/\/doi.org\/10.1016\/S1474-4422(23)00378-2. (PMID: 38101901)","journal-title":"Lancet Neurol"},{"issue":"3","key":"2709_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JPD-140364","volume":"4","author":"I Aviles-Olmos","year":"2014","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T (2014) Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease. J Parkinsons Dis 4(3):337\u2013344. https:\/\/doi.org\/10.3233\/JPD-140364. (PMID: 24662192)","journal-title":"J Parkinsons Dis"},{"issue":"7","key":"2709_CR6","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/mds.27721","volume":"34","author":"CB Carroll","year":"2019","unstructured":"Carroll CB, Wyse RKH, Grosset DG (2019) Statins and Parkinson\u2019s: A complex interaction. Mov Disord 34(7):934\u2013935. https:\/\/doi.org\/10.1002\/mds.27721. (PMID: 31322771)","journal-title":"Mov Disord"},{"issue":"4","key":"2709_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/0884533610373932","volume":"25","author":"R Kones","year":"2010","unstructured":"Kones R (2010) Parkinson\u2019s disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition. Nutr Clin Pract 25(4):371\u2013389. https:\/\/doi.org\/10.1177\/0884533610373932. (PMID: 20702843)","journal-title":"Nutr Clin Pract"},{"key":"2709_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2004.02.083","volume":"1037","author":"ML Selley","year":"2005","unstructured":"Selley ML (2005) Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 1037:1\u20136","journal-title":"Brain Res"},{"issue":"12","key":"2709_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014852.PMID:30896628;PMCID:PMC6709163","volume":"98","author":"J Yan","year":"2019","unstructured":"Yan J, Qiao L, Tian J, Liu A, Wu J, Huang J, Shen M, Lai X (2019) Effect of statins on Parkinson\u2019s disease: A systematic review and meta-analysis. Medicine (Baltimore) 98(12):e14852. https:\/\/doi.org\/10.1097\/MD.0000000000014852.PMID:30896628;PMCID:PMC6709163","journal-title":"Medicine (Baltimore)"},{"issue":"309","key":"2709_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbr.2016.04.046","volume":"1","author":"Z Sheng","year":"2016","unstructured":"Sheng Z, Jia X, Kang M (2016) Statin use and risk of Parkinson\u2019s disease: A meta-analysis. Behav Brain Res 1(309):29\u201334. https:\/\/doi.org\/10.1016\/j.bbr.2016.04.046. (Epub 2016 Apr 27 PMID: 27131781)","journal-title":"Behav Brain Res"},{"issue":"3","key":"2709_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/pds.4079","volume":"26","author":"K Bykov","year":"2017","unstructured":"Bykov K, Yoshida K, Weisskopf MG, Gagne JJ (2017) Confounding of the association between statins and Parkinson disease: systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 26(3):294\u2013300. https:\/\/doi.org\/10.1002\/pds.4079. (Epub 2016 Aug 16 PMID: 27527987)","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2709_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"2709_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"3","key":"2709_CR14","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3233\/JPD-212819.PMID:34958045;PMCID:PMC10141621","volume":"12","author":"MM Lewis","year":"2022","unstructured":"Lewis MM, Albertson RM, Du G, Kong L, Foy A, Huang X (2022) Parkinson\u2019s Disease Progression and Statins: Hydrophobicity Matters. J Parkinsons Dis 12(3):821\u2013830. https:\/\/doi.org\/10.3233\/JPD-212819.PMID:34958045;PMCID:PMC10141621","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"2709_CR15","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/mds.28474","volume":"36","author":"CH Lin","year":"2021","unstructured":"Lin CH, Chang CH, Tai CH, Cheng MF, Chen YC, Chao YT, Huang TL, Yen RF, Wu RM (2021) A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson\u2019s Disease. Mov Disord 36(5):1229\u20131237. https:\/\/doi.org\/10.1002\/mds.28474. (Epub 2021 Jan 15 PMID: 33449392)","journal-title":"Mov Disord"},{"key":"2709_CR16","doi-asserted-by":"publisher","unstructured":"Stevens KN, Creanor S, Jeffery A, Whone A, Zajicek J, Foggo A, Jones B, Chapman R, Cocking L, Wilks J, Webb D, Carroll C; PD STAT Study Group. Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2022 Dec 1;79(12):1232\u20131241. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3718. PMID: 36315128; PMCID: PMC9623477.","DOI":"10.1001\/jamaneurol.2022.3718"},{"key":"2709_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.phrs.2009.03.010","volume":"60","author":"E Mutez","year":"2009","unstructured":"Mutez E, Duhamel A, Defebvre L et al (2009) Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson\u2019s disease. Pharmacol Res 60:41\u201345. https:\/\/doi.org\/10.1016\/j.phrs.2009.03.010","journal-title":"Pharmacol Res"},{"issue":"1","key":"2709_CR18","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a008862","volume":"1","author":"CG Goetz","year":"2011","unstructured":"Goetz CG (2011) The history of Parkinson\u2019s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med 1(1):a008862. https:\/\/doi.org\/10.1101\/cshperspect.a008862","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2709_CR19","doi-asserted-by":"publisher","unstructured":"Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP. The Role of Glial Reaction and Inflammation in Parkinson\u2019s Disease. Ann N Y Acad Sci. 2003;991(1):214\u2013228. https:\/\/doi.org\/10.1111\/j.1749-6632.2003.tb07478.x","DOI":"10.1111\/j.1749-6632.2003.tb07478.x"},{"key":"2709_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1741-7015-5-20","volume":"5","author":"B Wolozin","year":"2007","unstructured":"Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson\u2019s disease. BMC Med 5:20. https:\/\/doi.org\/10.1186\/1741-7015-5-20","journal-title":"BMC Med"},{"key":"2709_CR21","doi-asserted-by":"publisher","unstructured":"Wahner AD, Bronstein JeffM, Bordelon YM, Ritz B. Statin Use and the Risk of Parkinson\u2019s Disease. Neurology. 2008;70(16 Pt 2):1418\u20131422. https:\/\/doi.org\/10.1212\/01.wnl.0000286942.14552.51","DOI":"10.1212\/01.wnl.0000286942.14552.51"},{"issue":"5","key":"2709_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2165\/00002018-200831050-00004","volume":"31","author":"C Becker","year":"2008","unstructured":"Becker C, Jick SS, Meier CR (2008) Use of statins and the risk of Parkinson\u2019s disease: a retrospective case-control study in the UK. Drug Saf 31(5):399\u2013407. https:\/\/doi.org\/10.2165\/00002018-200831050-00004","journal-title":"Drug Saf"},{"issue":"3","key":"2709_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152564","volume":"11","author":"S Bai","year":"2016","unstructured":"Bai S, Song Y, Huang X et al (2016) Statin Use and the Risk of Parkinson\u2019s Disease: An Updated Meta-Analysis. PLoS ONE 11(3):e0152564. https:\/\/doi.org\/10.1371\/journal.pone.0152564","journal-title":"PLoS ONE"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02709-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02709-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02709-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:04:23Z","timestamp":1757131463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02709-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2709"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02709-4","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors report no relationships that could be construed as a conflict of interest. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. There were no external funding sources for this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}